GlassScriptPhysician profile
Trinket L Edwards
NPI 1093053357
$4,014.82
in general payments reported to CMS, 2019-2025
28 companies · $720 in 2025
The $720 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,012 · 2022: $1,143 · 2023: $768 · 2024: $372 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,860.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $819.21 | 2021-2025 | Xtampza |
| Abbvie INC. | $772.06 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $344.45 | 2022 | |
| Forte Bio-Pharma LLC | $339.31 | 2021-2024 | Prolate, Nalocet |
| Pfizer INC. | $336.08 | 2023-2025 | |
| Medtronic, INC. | $182.46 | 2022-2025 | Inceptiv, Accurian |
| Tersera Therapeutics LLC | $133.35 | 2022-2023 | Prialt |
| Amgen INC. | $117.09 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.06 | 2022-2024 | Relistor |
| Almatica Pharma LLC | $104.01 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $82.72 | 2023-2024 | Horizant, Horizant |
| Scilex Pharmaceuticals INC. | $81.79 | 2022-2025 | Ztlido |
| Virtus Pharmaceuticals LLC | $78.43 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $68.21 | 2021-2022 | |
| Horizon Therapeutics Plc | $57.62 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $51.73 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $51.15 | 2025 | |
| Abbott Laboratories | $50.63 | 2021-2022 | |
| Valinor Pharma, LLC | $38.75 | 2023 | Movantik |
| Si-Bone, INC. | $38.44 | 2024 | |
| Lilly USA, LLC | $28.84 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $28.35 | 2022 | |
| Eisai INC. | $20.08 | 2021 | |
| Biodelivery Sciences International, INC. | $18.96 | 2021 | |
| Globus Medical, INC. | $18.23 | 2025 | Senza |
| Currax Pharmaceuticals LLC | $14.85 | 2021 | |
| Vertos Medical, INC. | $14.06 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trinket Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.